Endocrine Abstracts

Background: Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity in obese individuals. GLP-1 agonists, such as semaglutide, and SGLT-2 inhibitors, such as empagliflozin, are well known to be beneficial in NAFLD, while other incretins, like peptide tyrosine tyrosine 3-36 (PYY3-36), might be also useful for the treatment of NAFLD. We directly compared the effects of semaglutide alone and in combination with peptide tyrosine tyrosine 3-36 (PYY3-36), empagliflozin and...

Background: An activation of the hypothalamic-pituitary-adrenal (HPA) axis is a common observation in obese individuals. GLP-1 agonists, such as semaglutide, and SGLT-2 inhibitors, such as empagliflozin, are well known to be beneficial in obesity, while other incretins, like peptide tyrosine tyrosine 3-36 (PYY 3-36), might be also useful for the treatment of obesity. However, the effect of these substances on the adrenal gland is largely unknown. We directly compared the effec...

Background: Combinatory treatments with analogues of incretins might mimic the beneficial effects of bariatric surgery. We could show in the past that a combinatory treatment with PYY 3-36 and liraglutide leads to a similar body weight loss as Roux-en-Y gastric bypass (RYGB). We hypothesize that a combination of semaglutide and a modified PYY 3-36 analogue with increased selectivity for the neuropeptide Y receptor type 2 (NNC0165-1273) exceeds the weight-reducing effects of ba...